期刊文献+

急性肺栓塞患者溶栓治疗后凝血-纤溶指标的变化 被引量:1

原文传递
导出
摘要 美国每年约有10万人直接死于急性肺栓塞(Acute pulmonary thrombo-embolism, APT),另有10万人的死因与之相关。遗憾的是作为一项常规治疗措施,溶栓治疗后24h的血管阻塞率仅降低35%,第7天时则与单纯抗凝治疗无异。因而,我们着重研究了APT患者在常规溶栓、抗凝治疗后24h和7d凝血、纤溶指标与肺血管内皮细胞功能的变化,以期为该治疗方案的完善提供科学依据。
出处 《中华血液学杂志》 CAS CSCD 北大核心 2007年第3期206-208,共3页 Chinese Journal of Hematology
基金 天津市自然科学基金重点资助项目(013609011)
  • 相关文献

参考文献10

  • 1Braurrwald. Heart disease. 5th Edition. Science Press, 1999. 1582-1604.
  • 2Guidelines on diagnosis and management of acute pulmonary embolism. Task Force on Pulmonary Embolism, European Society of Cardiology. Eur Heart J, 2000, 21:1301-1336.
  • 3Briones A, Nauffal D, Villa P, et al. Clinical manifestations and prevalence of hypercoagulable states in patients with venous thromboembolic disease, Med Clin, 2001, 116: 201-205.
  • 4Flores J, Garcia-Avello A, Flores VM, et al. Tissue plasminogen activator plasma levels as a potential diagnostic aid in acute pulmonary embolism. Arch Pathol Lab Med,2003,127:310-315.
  • 5陈永利,张敬霞,袁志明,毕研永,王佩显.纤溶酶原激活物及其抑制剂-1的血浆含量测定在急性肺血栓栓塞症中的意义[J].中华急诊医学杂志,2005,14(3):191-194. 被引量:12
  • 6Comerota AJ, Chouhan V, Harada RN, et al. The fibrinolytic effects of intermittent pneumatic compression: mechanism of enhanced fibrinolysis. Ann Surg, 1997, 226: 306-313.
  • 7Levi M, Biemond B J, Friederich PW, et al. Novel low-molecular-weight inhibitor of PAI-1 ( XR5118 ) promotes endogenous fibrinolysis and reduces postthrombolysis thrombus growth in rabbits. Circulation,1997, 96:916-921.
  • 8杨冀萍,张聪敏,关继涛,石玉珍,王保法.肺血栓栓塞症患者血小板功能和血清抗心磷脂抗体的变化及意义[J].中华结核和呼吸杂志,2004,27(11):731-734. 被引量:8
  • 9Izbicki G, Bairey O, Shitrit D, et al. Increased thromboembolic events after lung transplantation. Chest, 2006,129 : 412-416.
  • 10Kester T, Rosendaal FR, Brier E, et al. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis ( Leiden Thrombophilia Study).Blood, 1995, 85 : 2756-2761.

二级参考文献17

  • 1周永列,刘建栋.D-二聚体的测定及其临床意义[J].国外医学(临床生物化学与检验学分册),1996,17(1):4-6. 被引量:121
  • 2Gram J, Sidelmann J, Jeapersen J. Does low protein concentration of tissue-type plasminogen activator predict a low risk of spontaneous deep vein thrombosis? Thromb Haemost, 1995, 74(2): 718-721.
  • 3Segui R, Estelles A, Mira Y, et al. PAI-1 promotor 4G/5G genptype as an additional risk factor for venous thrombosis in subjects with genetic thrombophilic defects. Br J Haematol, 2000, 111(1): 122-128.
  • 4Lang IM, Moser KM, Schleef RR. Elevated expression of urokinase-like plasminogen activator and plasminogen activator inhibitor type 1 during the vascular remodeling associated with pulmonary thromboembolism. Arterioscler Thromb Vasc Biol, 1998, 18(5):808-815.
  • 5Panahloo A, Mohamed-Ali V, Lane A, et al. Determinants of plasminogen activator inhibitor-1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor-I gene. Diabetes, 1995, 44(1):37-42.
  • 6Flores J, Garcia-Avello A, Flores VM, et al. Tissue plasminogen activator plasma levels as a potential diagnostic aid in acute pulmonary embolism. Arch Pathol Lab Med, 2003, 127(2):310-315.
  • 7Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med, 1998,158:585-593.
  • 8Nielsen HK. Pathophysiology of venous thromboembolism. Semin Thromb Hemost, 1991,17 Suppl 3:250-253.
  • 9Garcia-Szabo R, Johnson A, Malik AB. Thromboxane increases pulmonary vascular resistance and transvascular fluid and protein exchange after pulmonary microembolism. Prostaglandins, 1988,35:707-721.
  • 10Madan M, Berkowitz SD, Tcheng JE. Glycoprotein Ⅱb/Ⅲa integrin blockade. Circulation,1998,98:2629-2635.

共引文献18

同被引文献12

引证文献1

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部